Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
CCL parancs
CCL
Összesen 2 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM106190
035-os BibID:
(WoS)000922296500001 (Scopus)85142183130
Első szerző:
Pagano, Livio
Cím:
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from the EPICOVIDEHA survey / Pagano Livio, Salmanton-García Jon, Marchesi Francesco, Blennow Ola, Gomes da Silva Maria, Glenthj Andreas, van Doesum Jaap, Bilgin Yavuz M., López-García Alberto, Itri Federico, Nunes Rodrigues Raquel, Weinbergerová Barbora, Farina Francesca, Dragonetti Giulia, Berg Venemyr Caroline, van Praet Jens, Jaksic Ozren, Valkovic Toni, Falces-Romero Iker, Martín-Pérez Sonia, Jiménez Moraima, Dávila-Valls Julio, Schönlein Martin, Ammatuna Emanuele, Meers Stef, Delia Mario, Stojanoski Zlate, Nordlander Anna, Lahmer Tobias, Imre Pinczés László, Buquicchio Caterina, Piukovics Klára, Ormazabal-Vélez Irati, Fracchiolla Nicola, Samarkos Michail, Méndez Gustavo-Adolfo, Hernández-Rivas José-Ángel, Espigado Ildefonso, Cernan Martin, Petzer Verena, Lamure Sylvain, di Blasi Roberta, Marques de Almedia Joyce, Dargenio Michelina, Biernat Monika M., Sciume Mariarita, de Ramón Cristina, de Jonge Nick, Batinic Josip, Aujayeb Avinash, Marchetti Monia, Fouquet Guillemette, Fernández Noemí, Zambrotta Giovanni, Sacchi Maria Vittoria, Guidetti Anna, Demirkan Fatih, Prezioso Lucia, Rácil Zdenek, Nucci Marcio, Mladenovic Milos, Liévin Raphaël, Hanáková Michaela, Gräfe Stefanie, Sili Uluhan, Machado Marina, Cattaneo Chiara, Adzic-Vukicevic Tatjana, Verga Luisa, Labrador Jorge, Rahimli Laman, Bonanni Matteo, Passamonti Francesco, Pagliuca Antonio, Corradini Paolo, Hoenigl Martin, Koehler Philipp, Busca Alessandro, Cornely Oliver A., EPICOVIDEHA Survey
Dátum:
2022
ISSN:
0006-4971
Megjegyzések:
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccination. Adult patients with HM, >= 1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received <= 2 vaccine doses before COVID-19 (1419, 91%), mostly mRNAbased (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P <.001), active HM (P <.001), and severe and critical COVID-19 (P =.007 and P <.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P <.001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P <.001) or combined with antivirals (P =.009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:
Blood. - 140 : 26 (2022), p. 2773-2787. -
További szerzők:
Salmanton-García, Jon
Marchesi, Francesco
Blennow, Ola
Gomes Da Silva, Maria
Glenthj, Andreas
van Doesum, Jaap
Bilgin, Yavuz M.
López-García, Alberto
Itri, Federico
Nunes Rodrigues, Raquel
Weinbergerová, Barbora
Farina, Francesca
Dragonetti, Giulia
Berg Venemyr, Caroline
van Praet, Jens
Jaksic, Ozren
Valkovic, Toni
Falces-Romero, Iker
Martín-Pérez, Sonia
Jiménez, Moraima
Dávila-Valls, Julio
Schönlein, Martin
Ammatuna, Emanuele
Meers, Stef
Delia, Mario
Stojanoski, Zlate
Nordlander, Anna
Lahmer, Tobias
Pinczés László Imre (1990-) (hematológus)
Buquicchio, Caterina
Piukovics Klára
Ormazabal-Vélez, Irati
Fracchiolla, Nicola S.
Samarkos, Michail
Méndez, Gustavo-Adolfo
Hernández-Rivas, José-Ángel
Espigado, Ildefonso
Cernan, Martin
Petzer, Verena
Lamure, Sylvain
Di Blasi, Roberta
Marques de Almeida, Joyce
Dargenio, Michelina
Biernat, Monika M.
Sciumè, Mariarita
De Ramón, Cristina
de Jonge, Nick
Batinić, Josip
Aujayeb, Avinash
Marchetti, Monia
Fouquet, Guillemette
Fernández, Noemí
Zambrotta, Giovanni Paolo Maria
Sacchi, Maria Vittoria
Guidetti, Anna
Demirkan, Fatih
Prezioso, Lucia
Ráčil, Zdenĕk
Nucci, Marcio
Mladenović, Miloš
Liévin, Raphaël
Hanáková, Michaela
Gräfe, Stefanie
Sili, Uluhan
Machado, Marina
Cattaneo, Chiara
Adžić-Vukičević, Tatjana
Verga, Luisa
Labrador, Jorge
Rahimli, Laman
Bonanni, Matteo
Passamonti, Francesco
Pagliuca, Antonio
Corradini, Paolo
Hoenigl, Martin
Koehler, Philipp
Busca, Alessandro
Cornely, Oliver Andreas
EPICOVIDEHA Survey
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
2.
001-es BibID:
BIBFORM113120
035-os BibID:
(cikkazonosító)101939 (scopus)85151507775
Első szerző:
Salmanton-García, Jon
Cím:
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies : a report from the EPICOVIDEHA registry / Salmanton-García Jon, Marchesi Francesco, Gomes da Silva Maria, Farina Francesca, Dávila-Valls Julio, Bilgin Yavuz M., Glenthj Andreas, Falces-Romero Iker, Van Doesum Jaap, Labrador Jorge, Buquicchio Caterina, El-Ashwah Shaimaa, Petzer Verena, Van Praet Jens, Schönlein Martin, Dargenio Michelina, Méndez Gustavo-Adolfo, Meers Stef, Itri Federico, Giordano Antonio, Pinczés László Imre, Espigado Ildefonso, Stojanoski Zlate, López-García Alberto, Prezioso Lucia, Jaksic Ozren, Vena Antonio, Fracchiolla Nicola S., González-López Tomás José, Colovic Natasa, Delia Mario, Weinbergerová Barbora, Marchetti Monia, Marques de Almeida Joyce, Finizio Olimpia, Besson Caroline, Biernat Monika M., Valkovic Toni, Lahmer Tobias, Cuccaro Annarosa, Ormazabal-Vélez Irati, Batinic Josip, Fernández Noemí, De Jonge Nick, Tascini Carlo, Anastasopoulou Amalia N., Duléry Rémy, Del Principe Maria Ilaria, Plantefeve Gaëtan, Papa Mario Virgilio, Nucci, Marcio; Jiménez, Moraima; Aujayeb, Avinash; Hernández-Rivas, José-Ángel; Merelli, Maria; Cattaneo, Chiara; Blennow, Ola; Nordlander, Anna; Cabirta, Alba; Varricchio, Gina; Sacchi, Maria Vittoria; Cordoba, Raul; Arellano, Elena; Gräfe, Stefanie K.; Wolf, Dominik, Emarah Ziad, Ammatuna Emanuele, Hersby Ditte Stampe, Martín-Pérez Sonia, Nunes Rodrigues, Raquel Rahimli, Laman, Pagano Livio, Cornely Oliver A., EPICOVIDEHA registry
Dátum:
2023
ISSN:
2589-5370
Megjegyzések:
Background Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. eClinicalMedicine 2023;58: 101939 Published Online 6 April 2023 https://doi.org/10. 1016/j.eclinm.2023. 101939 Articles 2 www.thelancet.com Vol 58 April, 2023 Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan?Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ?1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448?4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619?8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093?0.732) and obesity (aOR 0.105, 95%CI 0.014?0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir.
Tárgyszavak:
Orvostudományok
Egészségtudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Nirmatrelvir
SARS-CoV-2
Haematology
Malignancy
COVID-19
Megjelenés:
eClinicalMedicine. - 58 (2023), p. 1-19. -
További szerzők:
Marchesi, Francesco
Gomes Da Silva, Maria
Farina, Francesca
Dávila-Valls, Julio
Bilgin, Yavuz M.
Glenthj, Andreas
Falces-Romero, Iker
van Doesum, Jaap
Labrador, Jorge
Buquicchio, Caterina
El-Ashwah, Shaimaa
Petzer, Verena
van Praet, Jens
Schönlein, Martin
Dargenio, Michelina
Méndez, Gustavo-Adolfo
Meers, Stef
Itri, Federico
Giordano, Antonio
Pinczés László Imre (1990-) (hematológus)
Espigado, Ildefonso
Stojanoski, Zlate
López-García, Alberto
Prezioso, Lucia
Jaksic, Ozren
Vena, Antonio
Fracchiolla, Nicola S.
González-López, Tomás José
Colovic, Natasa
Delia, Mario
Weinbergerová, Barbora
Marchetti, Monia
Marques de Almeida, Joyce
Finizio, Olimpia
Besson, Caroline
Biernat, Monika M.
Valkovic, Toni
Lahmer, Tobias
Cuccaro, Annarosa
Ormazabal-Vélez, Irati
Batinić, Josip
Fernández, Noemí
de Jonge, Nick
Tascini, Carlo
Anastasopoulou, Amalia N.
Duléry, Rémy
Del Principe, Maria Ilaria
Plantefeve, Gaëtan
Papa, Mario Virgilio
Nucci, Marcio
Jiménez, Moraima
Aujayeb, Avinash
Hernández-Rivas, José-Ángel
Merelli, Maria
Cattaneo, Chiara
Blennow, Ola
Nordlander, Anna
Cabirta, Alba
Varricchio, Gina
Sacchi, Maria Vittoria
Cordoba, Raul
Arellano, Elena
Gräfe, Stefanie K.
Wolf, Dominik
Emarah, Ziad
Ammatuna, Emanuele
Hersby, Ditte Stampe
Martín-Pérez, Sonia
Nunes Rodrigues, Raquel
Rahimli, Laman
Pagano, Livio
Cornely, Oliver Andreas
EPICOVIDEHA registry
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.